Physiologic estradiol replacement therapy and cardiac structure and function in normal postmenopausal women: a randomized, double-blind, placebo-controlled, crossover trial.

Authors: Snabes MC, Payne JP, Kopelen HA, Dunn JK, Young RL, Zoghbi WA.

Publication Year: 1997

Citation: Obstet Gynecol 1997;89(3):332-9.

In a randomized, double-blind, placebo-controlled, crossover clinical trial of 31 postmenopausal women, average age 59.7 years, using 2.0 mg of oral estradiol (E2) daily, the authors investigated the effects of estradiol on cardiac function and structure. This study did not include the use of progestins with estrogen. 12 weeks of E2 therapy showed no change in left ventricular thickness or mass, left atrial size or aortic size. There was a small but significant increase in left ventricular end-diastolic volume but it was not associated with change in end-systolic volume or ejection fraction changes. Heart rate and systolic and diastolic pressures were unchanged after 3 months of treatment. Time-velocity integral of flow and peak flow velocities were unaffected by E2 treatment. Authors concluded that estrogen replacement therapy did not affect cardiac structure or size in normal postmenopausal women (after 12 weeks of treatment).